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ABSTRACT: Secondary piperidines are ideal pharmaceutical 
building blocks owing to the prevalence of piperidines in 
commercial drugs. Here, we report an electrochemical method for 
cyanation of the heterocycle adjacent to nitrogen without requiring 
protection or substitution of the N–H bond. The reaction utilizes 
ABNO (9-azabicyclononane N-oxyl) as a catalytic mediator. 
Electrochemical oxidation of ABNO generates the corresponding 
oxoammonium species, which promotes dehydrogenation of the 2° 
piperidine to the cyclic imine, followed by addition of cyanide. The 
low-potential, mediated electrolysis process is compatible with a 
wide range of heterocyclic and oxidatively sensitive substituents on 
the piperidine ring and enables synthesis of unnatural amino acids.  
Strategic building blocks are commonly used in drug discovery 
to create or modify bioactive core structures, and efficient methods 
for diversification of commercially available building blocks could 
have broad impact in medicinal chemistry.1 Piperidines are the 
most common heterocycle found in FDA-approved drugs2 owing 
to their favorable pharmacokinetic properties that contribute to 
improved clinical success (Scheme 1A).3 Secondary piperidines 
represent ideal targets for chemical modification, and effective 
methods could greatly expand this pool of available building 
blocks. Whereas C–H functionalization adjacent to nitrogen in 
cyclic amines has been the focus of considerable attention,4 the vast 
majority of precedents use N-protected (i.e., N-acyl) or N-aryl/alkyl 
3° amine derivatives that are less versatile as pharmaceutical 
building blocks.5,6 Amine protection/deprotection hampers 
efficient utilization of the former substrates, while fixed 
substitution of the N-aryl/alkyl derivatives limits incorporation of 
these compounds into more complex structures. Here, we report an 
electrochemical method for oxidative α-cyanation of diverse 2° 
piperidines. The method is enabled by the use of ABNO (9-
azabicyclononane N-oxyl) as a catalytic mediator that exhibits 
broad functional group compatibility. 
Nitriles are versatile functional groups that are readily converted 
into other substituents, including carboxylic acids, amides, ketones 
and amines, among others.7 This versatility underlies the extensive 
efforts directed toward α-cyanation of piperidine and other amine 
derivatives (Scheme 1B).8 Synthetically useful precedents, 
however, are limited to activated substrates (e.g., 
tetrahydroisoquinolines) and the 3° amine/amide derivatives noted 
above. No general methods are available for analogous cyanation 
of 2° piperidines,9 reflecting the susceptibility of cyclic imines to 
undergo decomposition.10, 11 
Scheme 1. Context and Strategy for α-Cyanation of 2° Piperidines 
  
Precedents for electrochemical oxidation of amines typically 
feature 3° derivatives12 and/or are initiated by outer sphere single-
electron transfer (ET). Subsequent rapid proton and electron 
transfer (PT-ET) affords an iminium ion.13 We recently showed 
that use of an aminoxyl mediator bypasses this conventional ET-
PT-ET sequence by undergoing electrochemical oxidation to an 
oxoammonium species that promotes direct hydride transfer from 
the substrate.14,15 The aminoxyl-mediated reactions operate at 
much lower electrode potentials (by > 1 V), thereby greatly 
expanding the functional group compatibility and substrate scope. 
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Here, we demonstrate that analogous principles may be applied to 
enable efficient α-cyanation of 2° piperidines bearing diverse 
pharmaceutically relevant substituents (Scheme 1C). 
We initiated our studies by investigating the redox behavior of 
4-phenylpiperidine 1a by cyclic voltammetry (CV) in the absence 
and presence of ABNO (Figure 1).16 Substrate 1a exhibits an 
irreversible anodic CV feature at 739 mV (Figure 1, green trace; all 
potentials are reported relative to Fc/Fc+), while ABNO, which was 
selected as a low-potential sterically unhindered aminoxyl 
mediator,17 exhibits a reversible CV trace with E1/2 = 195 mV 
(Figure 1, gray trace). CV analysis of a solution containing both 1a 
and ABNO reveals a significant increase in the anodic feature at 
the ABNO redox potential, with a corresponding decrease in the 
cathodic feature (Figure 1, red trace). This behavior implicates 
reaction of ABNO+ with the substrate and electrochemical 
regeneration of ABNO+ on the CV time scale (cf. Scheme 1c). 
Complete disappearance of the anodic feature corresponding to 1a 
under these conditions is consistent with consumption of the 
substrate from the electrode surface via reaction with ABNO+. The 
large difference between the anodic peak potentials of ABNO and 
1a (ΔEp > 500 mV; cf. green vs red trace) highlights the lower 
electrode potential that arises when substrate oxidation proceeds 
via ABNO-mediated hydride transfer, rather than electrode-
initiated electron transfer.18  
 
 
Figure 1. CVs (0.1 V/s) in MeCN (5 mL) and NaClO4 (0.1 M) of: 
ABNO (1 mM) (gray trace); 4-phenyl piperidine 1a (2 mM) (green 
trace); ABNO (1 mM) and 4-phenyl piperidine (2 mM) (red trace). 
 
Efforts then shifted to bulk electrolysis studies in order to 
explore optimal conditions for substrate cyanation. The reactions 
were conducted under constant-current conditions (1–3 mA) in an 
undivided cell with a graphite rod working electrode and Pt wire 
counter electrode. TMSCN was used as an easily handled source of 
cyanide nucleophile. Initial attempts to perform direct oxidation of 
the substrate at the electrode (i.e., in the absence of a mediator) 
resulted in only low yield of the desired product 2a (19%, Table 1, 
entry 1). Inclusion of 10 mol% ABNO in the reaction, under 
otherwise identical conditions, nearly doubled the yield of 2a 
(37%, entry 2). One equivalent of hexafluoroisopropanol (HFIP) 
was included in the reaction as a proton source to facilitate 
production of H2 at the cathode (cf. BH+ in Scheme 1C), which also 
generates an alkoxide base that can promote proton-coupled 
oxidation of ABNO-H to ABNO+ at the anode (cf. Scheme 1C).19 
Consistent with this hypothesis, the yield improved considerably 
upon adding HFIP, 1 equiv; 54% yield, entry 3) as an additive (see 
below for further discussion). 
Testing of other aminoxyl mediators clearly indicated the 
importance of steric effects as the primary indicator of mediator 
effectiveness.20 Specifically, TEMPO and 4-acetamidoTEMPO 
(ACT) have higher redox potentials than ABNO, but they afforded  
 
 
 
Table 1. Bulk Electrolysis Optimization Data.  
  
aNMR yields against a mesitylene internal standard. Isolated yield. bHFIP 
= hexafluoroisopropanol. cReaction performed in commercial BASi bulk 
electrolysis cell on 1 g scale using RVC working electrode. dReaction 
performed using ElectraSyn 2.0. 
 
lower yields of 2a (entries 4 and 5). KetoABNO exhibited the 
highest yield, but, as its higher redox potential could interfere with 
functional-group compatibility, we explored further optimization 
of the reaction with ABNO as the mediator. Increasing the 
electrolysis current from 1 to 3 mA led to an increase in yield from 
54% to 66% (entries 3 and 7). Further improvement was achieved 
by replacing HFIP with MeOH as the protic additive and reducing 
the stoichiometry to 0.5 equiv, ultimately affording 84% yield of 
2a (entries 7–10). To ensure reproducibility, the optimized reaction 
conditions were directly implemented in two commercially 
available bulk electrolysis cells, one from BASi and the ElectraSyn 
2.0 unit from IKA, with the former conducted on 1 g scale (entries 
11 and 12). Both reactions afforded 2a in good yield. 
Analysis of the constant current electrolysis traces provides 
valuable insights into the ABNO-mediated reactions (Figure 2). 
Under the optimized reaction conditions (red trace) the electrode 
potential needed to sustain 3 mA current is low (approx. 150–250 
mV) and is stable throughout the entire reaction. In the absence of 
MeOH (blue trace), a low potential is observed only when the 
charge passed is less than that needed for electrochemical oxidation 
of ABNO to ABNO+. The increase in potential beyond this point  
 
 
Figure 2. Bulk electrolysis in MeCN, TBAPF6 (0.1 M), TMSCN (1.5 
equiv.) and 1a (0.3 mmol) with/without ABNO (10 mol%) and/or 
MeOH (0.5 equiv.).16 MB = mass balance.  
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(to approx. 600-700 mV) is attributed to the lack of an effective 
Brønsted base (i.e., no methoxide is available) to support proton-
coupled oxidation of ABNOH to ABNO+. In the absence of both 
MeOH and ABNO (green trace), a much higher electrode potential 
is needed to support the 3 mA current. The initial observed 
potential is similar to that expected from the CV studies (cf. Figure 
1); however, this potential rises significantly during the reaction, 
possibly arising from fouling of the electrode by reactive 
intermediates generated in the direct electrolysis process.21 The 
reaction yield correlates inversely with the potential needed to 
sustain the reaction, demonstrating the benefit of pairing a mediator 
with an appropriate proton shuttle in the undivided cell.  
The optimized conditions were then tested on a broad collection 
of commercially available 2° piperidines (Table 2A). 4-Substituted 
piperidines are especially readily available, and good-to-excellent 
yields of the corresponding α-cyanopiperidines were obtained for 
substrates bearing a diverse array of functional groups, including 
aryl, aryl halide, aryl ether, amide, ester, pyridine and related 
heteroaryl derivatives, and azoles, among other groups (3a–3r). 
The method even tolerates an unprotected 2° alcohol (3x), 
indicating that amine oxidation is favored over the well-established 
aminoxyl-mediated alcohol oxidation.15 The products were 
primarily isolated as the p-toluenesulfonic acid salts. Analytically 
pure electrolyte salt (TBAPF6) was also recovered from the 
reaction mixture and reused. High diastereoselectivity, often 
reflecting only a single diastereomer, is observed in all cases where 
the substituent is large enough to bias the ring conformation (3a–
3p, 3s). The favored anti relationship between the cyano group and 
substituent was confirmed by nOe measurements and X-ray 
crystallography. The observed stereochemistry is rationalized by 
axial attack of cyanide on the intermediate imine and aligns with 
stereochemical models that have been reported by Houk22 and 
Cieplak.23 A mixture is observed in two cases when the substituent 
is smaller (3x, 3y) and in a bicyclic pyrrolidine substrate (3ad). The 
latter result demonstrates that the method is applicable to 
heterocycles beyond piperidines, as further exemplified by the 
reaction of the parent pyrrolidine, (3ac), an azepane (3ab), and 
morpholine (3u). Piperidine substitution in the 2- and 3- positions 
leads to highly regioselective cyanation at the less hindered 
position, suggesting that steric accessibility overrides 
thermodynamic considerations (3s, 3v, 3w). This observation is 
also evident from the selectivity observed with the azepane 
derivative 3ab, where the benzylic position is avoided in favor of 
the more accessible site. 
For a substrate containing both an unprotected and a Boc-
protected 2° piperidine, cyanation only occurred on the unprotected 
piperidine ring (3q). On the other hand, 2° piperidine substrates 
bearing 5- or 6-membered cyclic 3° alkylamine substituents 
undergo preferential cyanation on the alkylamine ring (3z, 3aa), 
presumably reflecting the enhanced hydricity of the C–H bonds at 
this site.16 Ineffective substrates primarily corresponded to 
substrates that were not soluble in the reaction medium.16  
Table 2. Substrate Scope for Electrochemical α-Cyanation of 2° Piperidines (A) and Cyanation/Hydrolysis to Generate Pipecolic Acids (B).a 
 
aReaction performed on 0.3 mmol scale. Isolated yields are reported. 
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The relevance of this method for medicinal chemistry is evident 
from a number of substrates that feature functional groups directly 
corresponding to active pharmaceuticals and drug candidates in 
Scheme 1A. Examples include risperidone (3j),24 two receptor 
antagonists (3p and 3r)25,26 and the HIV drug, Nelfinavir (3i).27 
Each of the corresponding α-cyanation products was isolated in 
diastereomeric purity. The low potential and mild conditions that 
make this method applicable to building block diversification also 
make it amenable to late-stage functionalization, as revealed by the 
cyanation of the anti-depressant Amitifadine (3ad), which 
proceeded in 48% yield.  
The hydrolysis of the nitriles to carboxylic acids provides an 
efficient means to generate non-natural amino acids. To 
demonstrate this concept, several cyanation products were 
subjected directly to hydrolysis conditions, without isolation, to 
generate the corresponding carboxylic acid derivatives in excellent 
yields (4a–d, Table 2B).28 
In summary, we have developed a highly effective, user-friendly 
method for electrochemical α-cyanation of 2° piperidines. This 
class of molecules represents an especially important class of 
pharmaceutical building blocks. Use of ABNO as a hydride-
transfer mediator allows the reactions to proceed at low electrode 
potentials, thereby tolerating a broad array of important functional 
groups. C–H functionalization methods and related reactions of this 
type that enable direct building block diversification should have 
considerable utility in medicinal chemistry and drug discovery.  
ASSOCIATED CONTENT  
Supporting Information 
(1) (a) Krotko, D.; Chuprina, A.; Shivanyuk, A.; Tolmachev, A. 
Chim. Oggi Chem. Today 2010, 28, 16-17. (b) Goldberg, F. W.; Kettle, 
J. G.; Kogej, T.; Perry, M. W. D.; Tomkinson, N. P. Drug Discov. 
Today 2015, 20, 11–17. (c) Blakemore, D. C.; Castro, L.; Churcher, I.; 
Rees, D. C.; Thomas, A. W.; Wilson, D. M.; Wood, A. Nat. Chem. 
2018 10, 383-394. 
(2) Vitaku, E.; Smith, D. T.; Njardarson, J. T. J. Med. Chem. 2014, 
57, 10257–10274. 
(3) (a) Lovering, F.; Bikker, J.; Humblet, C. J. Med. Chem. 2009, 
52, 6752–6756. (b) Ritchie, T. J.; Macdonald, S. J. F.; Young, R. J.; 
Pickett, S. D. Drug Discov. Today 2011, 16, 164-171. (c) Ritchie, T. J.; 
Macdonald, S. J. F.; Peace, S.; Pickett, S. D.; Luscombe, C. N. Med. 
Chem. Commun. 2012, 3, 1062-1069. 
(4) Mitchell, E. A.; Peschiulli, A.; Lefevre, N.; Meerpoel, L.; Maes, 
B. U. W. Chem. Eur. J. 2012, 18, 10092-10142. 
(5) For an important exception, see: Chen, W.; Ma, L.; Paul, A.; 
Seidel, D. Nat. Chem. 2018, 10, 165-169. 
(6) The utility of cyclic secondary amines as building blocks is 
illustrated in the “SnAP” chemistry developed by Bode and coworkers 
Luescher, M. U.; Geoghegan, K.; Nichols, P. L.; Bode, J. W. 
Aldrichimica Acta 2015, 48, 43–48. 
(7) (a) Henry, R. A. J. Org. Chem. 1959, 24, 1363–1364. (b) 
Portevin, B.; Benoist, A.; Rémond, G.; Hervé, Y.; Vincent, M.; 
Lepagnol, J.; De Nanteuil, G. J. Med. Chem. 1996, 39, 2379–2391. (c) 
Branch, C. L.; Johnson, C. N.; Stemp, G.; Thewlis, K. U.S. Patent 
6,677,354, Jan. 13, 2004. (d) Ma, Y.-N.; Yang, X.-J.; Pan, L.; Hou, Z.; 
Geng, H.-L.; Song, X.-P.; Zhou, L.; Miao, F. Chem. Pharm. Bull. 2013, 
61, 204–211. (e) Cioffi, C. L.; Liu, S.; Wolf, M. A.; Guzzo, P. R.; 
Sadalapure, K.; Parthasarathy, V.; Loong, D. T. J.; Maeng, J.-H.; 
Carulli, E.; Fang, X.; Karunakaran, K.; Matta, L.; Choo, S.-H.; 
Panduga, S.; Buckle, R. N.; Davis, R. N.; Sakwa, S. A.; Gupta, P.; 
Sargent, B. J.; Moore, N. A.; Luche, M. M.; Carr, G. J.; Khmelnitsky, 
Y. L.; Ismail, J.; Chung, M.; Bai, M.; Leong, W. Y.; Sachdev, N.; 
Swaminathan, S.; Mhyre, A. J. J. Med. Chem. 2016, 59, 8473-8494. (f) 
Experimental procedures, reaction optimization, and product 
characterization data. The Supporting Information is available free 
of charge on the ACS Publications website. 
AUTHOR INFORMATION 
Corresponding Author 
stahl@chem.wisc.edu 
Present Addresses 
†School of Chemistry, University of Bristol, Bristol, BS8 1TS, UK 
‡Boehringer Ingelheim Pharma GmbH & Co. KG, Medicinal 
Chemistry, Birkendorfer Strasse 65, 88397 Biberach an der Riss, 
Germany 
 
Notes 
The authors declare no competing financial interests. 
ACKNOWLEDGMENT  
We thank Ilia Guzei and Manar Alherech (UW) for assistance with 
X-ray crystallography and NMR spectroscopy, respectively, Fei 
Wang (UW) for preliminary investigations, Damian Hruszkewycz 
(UW) for synthesis of 1r, and Matthew Graaf (AbbVie) for helpful 
discussions. We thank IKA for their donation of an ElectraSyn 2.0 
apparatus. Financial support for this project was provided by the 
NIH (R01 GM100143) and AbbVie. Spectroscopic instrumentation 
was supported by a gift from Paul. J. Bender, NSF (CHE- 
1048642), and NIH (1S10 OD020022-1). 
REFERENCES
Blaskovich, M. A. T. J. Med. Chem. 2016, 59, 10807-10836. (g) 
Fuentes de Arriba, Á. L.; Lenci, E.; Sonawane, M.; Formery, O.; 
Dixon, D. J. Angew. Chem. Int. Ed. 2017, 56, 3655–3659. (h) Jaegli, 
S.; Schmidt, T.; Oftring, A.; Panchenko, A.; Dahmen, K.; Molt, O. U.S. 
Patent 9,695,121, Jul. 4, 2017. 
(8) For leading references, see: (a) Chiba, T.; Takata, Y. J. Org. 
Chem. 1977, 42, 2973–2977. (b) Le Gall, E.; Hurvois, J.-P.; Renaud, 
T.; Moinet, C.; Tallec, A.; Uriac, P. Sinbandhit, S.; Toupet, L. Liebigs 
Ann. 1997, 2089–2101. (c) Tajima, T.; Nakajima, A. J. Am. Chem. Soc. 
2008, 130, 10496–10497. (d) Han, W.; Ofial, A. R. Chem. Commun. 
2009, 5024-5026. (e) Libendi, S. S.; Demizu, Y.; Onomura, O. Org. 
Biomol. Chem. 2009, 7, 351–356. (f) Allen, J. M.; Lambert, T. H. J. 
Am. Chem. Soc. 2011, 133, 1260-1262. (g) Rueping, M.; Zhu, S.; 
Koenigs, R. Chem. Commun. 2011, 47, 12709-12711. (h) Zhang, Y.; 
Peng, H.; Zhang, M.; Cheng, Y.; Zhu, C. Chem. Commun. 2011, 47, 
2354–2356. (i) Reddy, K. H. V.; Satish, G.; Reddy, V. P.; Kumar, B. 
S. P. A.; Nageswar, Y. V. D. RSC Adv. 2012, 2, 11084-11088. (j) Ma, 
L.; Chen, W.; Seidel, D. J. Am. Chem. Soc. 2012, 134, 15305–15308. 
(k) Lin, A.; Peng, H.; Abdukader, A.; Zhu, C. Eur. J. Org. Chem. 2013, 
7286–7290. (l) Sakai, N.; Mutsuro, A.; Ikeda, R.; Konakahara, T. 
Synlett 2013, 24, 1283–1285. (m) Kumar, S.; Kumar, P.; Jain, S. L. 
RSC Adv. 2013, 3, 24013-24016. (n) Hoshikawa, T.; Yoshioka, S.; 
Kamijo, S.; Inoue, M. Synthesis 2013, 45, 874–887. (o) Yan, C.; Liu, 
Y.; Wang, Q. RSC Adv. 2014, 4, 60075–60078. (p) Nauth, A. M.; Otto, 
N.; Opatz, T. Adv. Synth. Catal. 2015, 357, 3424–3428. (q) Pacheco, J. 
C. O.; Lipp, A.; Nauth, A. M.; Acke, F.; Dietz, J.-P.; Opatz, T. Chem. 
Eur. J. 2016, 22, 5409–5415. (r) Wakaki, T.; Sakai, K.; Enomoto, T.; 
Kondo, M.; Oisaki, K.; Kanai, M. Chem. Eur. J. 2018, 24, 8051-8055. 
(9) For isolated precedents, see: (a) Barton, D. H. R.; Billion, A.; 
Boivin, J. Tetrahedron Lett. 1985, 26, 1229–1232. (b) Troyanskii, É. 
I.; Ioffe, V. A.; Nikishin, G. I. Russ. Chem. Bull. 1985, 34, 2537–2546. 
(c) Moriarty, R. M.; Vaid, R. K.; Duncan, M. P.; Ochiai, M.; Inenaga, 
M.; Nagao, Y. Tetrahedron Lett. 1988, 29, 6913–6916. (d) Ushakov, 
D. B.; Gilmore, K.; Kopetzki, D.; McQuade, D. T.; Seeberger, P. H. 
                                                
 
  
5 
                                                                              
 
Angew. Chem. Int. Ed. 2014, 53, 557-561. (e) Kumar, R.; Gleibner, E. 
H.; Tiu, E. G. V.; Yamakoshi, Y. Org. Lett. 2016, 18, 184-187. (f) 
Shen, H.; Hu, L.; Liu, Q.; Hussain, M. I.; Pan, J.; Huang, M.; Xiong, 
Y. Chem. Commun. 2016, 52, 2776-2779. 
(10) Mitch, C. H. Tetrahedron Lett. 1988, 29, 6831-6834. 
(11) Fandrick, D. R.; Hart, C. A.; Okafor, I. S.; Mercadante, M. A.; 
Sanyal, S.; Masters, J. T.; Sarvestani, M.; Fandrick, K. R.; Stockdill, J. 
L.; Grinberg, N.; Gonnella, N.; Lee, H.; Senanayake, C. H. Org. Lett. 
2016, 18, 6192-6195. 
(12) For an example employing a cation-pool strategy for Boc-
protected secondary amines, see: Yoshida, J.-I.; Suga, S.; Suzuki, S.; 
Kinomura, N.; Yamamoto, A.; Fujiwara, K. J. Am. Chem. Soc. 1999, 
121, 9546-9549. 
(13) This is the pathway proposed for classical Shono oxidations, 
for example: (a) Shono, T.; Hamaguchi, H.; Matsumura, Y. J. Am. 
Chem. Soc. 1975, 97, 4264-4268; (b) Shono, T.; Matsumura, Y.; 
Tsubata, K. J. Am. Chem. Soc. 1981, 103, 1172-1176. 
(14) Wang, F.; Rafiee, M.; Stahl, S. S. Angew. Chem. Int. Ed. 2018, 
57, 6686-6690.  
(15) For a comprehensive review of aminoxyl-mediated 
electrochemistry, see: Nutting, J. E.; Rafiee, M.; Stahl, S. S. Chem. Rev. 
2018, 118, 4834-4885. 
(16) See Supporting Information for details. 
(17) (a) Rafiee, M.; Miles, K. C.; Stahl, S. S. J. Am. Chem. Soc. 
2015, 137, 14751–14757. (b) Hickey, D. P.; Schiedler, D. A.; 
Matanovic, I.; Doan, P. V.; Atanassov, P.; Minteer, S. D.; Sigman, M. 
S. J. Am. Chem. Soc. 2015, 137, 16179-16186. 
(18) For related observations involving mediated hydrogen-atom 
transfer versus electron transfer, see: Rafiee, M.; Wang, F.; 
Hruszkewycz, D. P.; Stahl, S. S. J. Am. Chem. Soc. 2018, 140, 22-25. 
(19) Utley, J. H. P.; Nielsen, M. F.; Wyatt, P. B. Electrogenerated 
Bases and Nucleophiles. In Organic Electrochemistry; Revised and 
Expanded; Hammerich, O., Speiser, B., Eds.; CRC Press, 2015. 
(20) For previous studies of steric vs. electronic effects in aminoxyl-
mediated oxidation reactions, see ref. 17 and the following: Steves, J. 
E.; Stahl, S. S. J. Am. Chem. Soc. 2013, 135, 15742-15745. 
(21) (a) Andrieux, C. P.; Gonzalez, F.; Savéant, J.-M. J. Am. Chem. 
Soc. 1997, 119, 4292-4300. (b) Lennox, A. J. J.; Nutting, J. E.; Stahl, 
S. S. Chem. Sci. 2018, 9, 356-361. 
(22) Caramella, P.; Rondan, N. G.; Paddon-Row, M. N.; Houk, K. 
N. J. Am. Chem. Soc. 1981, 103, 2438-2440. 
(23) Cieplak, A. S. J. Am. Chem. Soc. 1981, 103, 4540-4552. 
(24) Colpaert, F. C. Nat. Rev. Drug Discov. 2003, 2, 315-320. 
(25) DeBaillie, A. C.; Jones, C. D.; Magnus, N. A.; Mateos, C.; 
Torrado, A.; Wepsiec, J. P.; Tokala, R.; Raje, P. Org. Process Res. Dev. 
2015, 19, 1568-1575 
(26) Evans, B. E.; Ponticello, G. S.; Hoffman, J. M. U.S. Patent 
5,952,351, Sep. 14, 1999. 
(27) Albizati, K. F.; Babu, S.; Birchler, A.; Busse, J. K.; Fugett, M.; 
Grubbs, A.; Haddach, A.; Pagan, M.; Potts, B.; Remarchuk, T.; Rieger, 
D.; Rodriguez, R.; Shanley, J.; Szendroi, R.; Tibbetts, T.; Whitten, K.; 
Borer, B. C. Tetrahedron Lett. 2001, 42, 6481-6485. 
(28) 1H NMR analysis of the cyanation crude mixture showed that 
near quantitative yields were obtained from the hydrolysis work-up and 
isolation. In two cases, the carboxylic acid product was isolated in 
higher yield than isolation of the cyanation precursor (cf. 4b and 4c vs. 
3b and 3j). 
  
6 
TOC Graphic 
 
+  –CN
+
ABNO
ABNO =
N
O
N
H
N
H
CN
N
H
OS
Cl
CN
N
NO
N
H
CN
F
O
N
N
H
CN N
H
CN
N
OO
tBuBuilding Block Diversification
Alpha 1A 
Adrenergic 
Receptor 
Antagonist
CN
N
N
N
H
R
N
H
CO2H
R R
H3O+
30 examples
